Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice.
暂无分享,去创建一个
[1] J. Armitage,et al. Reviews and Notes: Oncology: High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells , 1992, Annals of Internal Medicine.
[2] D. Williams,et al. Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. , 1993, Blood.
[3] A. Mazumder,et al. LYMPHOKINE‐ACTIVATED KILLER CELLS IN AUTOLOGOUS BONE MARROW TRANSPLANTATION EVIDENCE AGAINST INHIBITION OF ENGRAFTMENT IN VIvo , 1992, Transplantation.
[4] D. Longo,et al. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. , 1992, Blood.
[5] W. Urba,et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Longo,et al. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. , 1992, Journal of immunology.
[7] H. Gadner,et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. , 1992, Blood.
[8] W. Murphy,et al. Natural killer cells activated with interleukin 2 in vitro can be adoptively transferred and mediate hematopoietic histocompatibility‐1 antigen‐specific bone marrow rejection in vivo , 1990, European journal of immunology.
[9] L. Barnett,et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.
[10] M. K. Warren,et al. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. , 1990, The Journal of clinical investigation.
[11] G. Trinchieri,et al. Biology of Natural Killer Cells , 1989, Advances in Immunology.
[12] T. Sayers,et al. Differing Roles for Interleukin 2 and Interferon γ in the Augmentation of Mouse Peritoneal Natural Killer Cell Activity in vivo , 1989 .
[13] T. Hirano,et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. , 1989, Blood.
[14] J. Armitage,et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.
[15] W. Kuziel,et al. T cell receptor genes do not rearrange or express functional transcripts in natural killer cells of scid mice. , 1987, Journal of immunology.
[16] 藤盛 好啓. Effect of lymphokine-activated killer cell fraction on the development of human hematopoietic progenitor cells , 1987 .
[17] R. Welsh,et al. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo , 1985, The Journal of experimental medicine.
[18] R. Herberman,et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells , 1975, International journal of cancer.